Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) clinical trials
Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) is the lead sponsor of 3 current clinical trials in our China and Austria registers. None of its ClinicalTrials.gov trials is recruiting at the moment. The most common phase is Phase 1. The drugs named most often in its trials are RG002C0106. The most-studied condition is IgA Nephropathy (IgAN).
ClinicalTrials.gov trials by status
Trials by phase
Clinical trials sponsored by Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing)
3 on ClinicalTrials.gov| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Phase 1 Study to Evaluate RG002C0106 Injection in Healthy Participants
NCT07902245 · ClinicalTrials.gov ↗ · Safety Issues
Drug: RG002C0106 |
Phase 1 | Not yet open | 2026-12 | Austria |
|
A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy
NCT07305974 · ClinicalTrials.gov ↗ · IgA Nephropathy (IgAN)
Drug: RG002C0106 |
Phase 2 | Active, closed | 2025-09 | China |
|
A Study of RG002C0106 Injection in Adult Participants With Normal Renal Function and Mild-to-Moderate Renal Impairment
NCT07445906 · ClinicalTrials.gov ↗ · Renal Impairments, IgA Nephropathy (IgAN)
Drug: RG002C0106 |
Phase 1 | Active, closed | 2026-03 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs in Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) trials
1 compoundDrugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
Conditions in Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) trials
3 conditionsBy trial register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 0 |
| Clinical trials in Austria | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
Other sponsors in IgA Nephropathy (IgAN)
| Sponsor | Trials |
|---|---|
| Vera Therapeutics | 2 |
| Haisco Pharmaceutical Group | 2 |
| Biocity Biopharmaceutics | 1 |
| Wuhan Createrna Science and Technology | 1 |
Sponsors with the most current trials registered for this condition.
Questions about Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) trials
How many clinical trials does Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) sponsor?
Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) is the lead sponsor of 3 current trials on ClinicalTrials.gov in our China and Austria registers, as of the registry sync on 30 October 2026. Completed and withdrawn studies are not counted.
Are Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) trials recruiting?
Not at the moment. None of its 3 ClinicalTrials.gov trials is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Which drugs is Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) testing?
Its current trials name 1 drug or biological as interventions. The most frequent are RG002C0106 (3). The number in brackets is how many of its trials name each drug.
Where does this information come from?
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
How this page is built
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
- EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 30 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.